Recent

% | $
Quotes you view appear here for quick access.

Sangamo Biosciences Inc. Message Board

rvga128 240 posts  |  Last Activity: 7 hours ago Member since: Dec 5, 2003
SortNewest  |  Oldest  |  Highest Rated Expand all messages
  • Although no patient deaths in KTE-C19's trials have been reportedly caused by KTE-C19, there was one patient death reported last August. A review determined the death wasn't caused by KTE-C19, and the trial continued as planned. However, KTE-C19's trial also includes fludarabine as part of a patient pre-conditioning protocol, and neurotoxicity has been pretty commonly observed in trials -- but it's been "generally reversible."

    While CAR-T therapy may eventually revolutionize how doctors treat relapsing and recurring B-cell cancers, Juno Therapeutics' news raises the risk associated with owning CAR-T stocks. If Juno Therapeutics is right, that the deaths are due to fludarabine, then investors will need to adjust their models to allow for delayed commercialization. That's not a good thing.

    Further, if Juno Therapeutics' is right about fludarabine, it casts a shadow over Kite Pharma's trial, too. As a result, Kite Pharma is also a risky stock to buy.
    -----------------------------------------------------------------------------------------------------------------------------
    1. ZIOP should be the savior for CAR-T- through Rheoswitch.
    2. ADXS - is were smart money needs to move.

  • Let him rant. When he does not attention he will decompensate and will have to run to shrink to get on meds. Lol.

  • BMS tried to out beat Merck with results from lung cancer study. Merck got approval
    For lung cancer with 50% expression of PD1/PDL1 (T Cell/Tumor Cell). They looked at
    Those with more than 5% expression. But the assay to detect is not a reliable one and the is less reliable when the expression is low. They lost $4 billion but they do not care because they can soak it to US Healthcare System- these type of mistakes is they happened in Public Institutions will raise hell. They also picked second rate bioengineered ADRO vs the gem “Advaxis” platform.
    The good news is there are many competitors in PD1/PDL1 Space:
    These include Merck, AZN, PFE, Merch Serono (German) and Roche.
    Let's see who does their homework better and picks Advaxis over ADRO.
    Forbes had an article why this BMS disaster is a win for personalized cancer immunotherapy- an AMGN made a smart move before anybody could get it.
    -------------------------------------------------------------------------------------------------
    Folks (esp. LTSH) now hold on to your shares.

  • rvga128 rvga128 Aug 17, 2016 9:12 AM Flag

    I am not sure if they needed those $28.3 Million dollars. Just my opinion- backdoor entry for rich and connected.

  • Scientists from the United States have made an important step toward eliminating cancer recurrence by combining immunotherapy with chemotherapy. Specifically, they found that chemotherapy alone leads to two types of dormant cancer cells that are not killed outright and become resistant to additional chemotherapy, but when combined with immunotherapy, a majority of dormant cells also is destroyed. The report appears in the September 2016 issue of the Journal of Leukocyte Biology.
    Immunotherapy is all about timing, - said Masoud H. Manjili, a researcher involved in the work from the Department of Microbiology and Immunology, VCU School of Medicine, Richmond, Virginia. "The best way to apply immunotherapy as cancer prevention is during tumor dormancy to prevent advanced stage disease."
    To make this discovery, researchers treated breast cancer cells with a common chemotherapeutic agent. Nearly all of the cancer cells died as a result, but a residual population of tumor cells survived and became dormant. By measuring for the presence of a molecule associated with cell division, the scientists determined that this residual population of dormant cancer cells consisted of an indolent as well as a quiescent population. Then, they treated the dormant cells with a product of the immune system, they found that dormant cells were susceptible to immunotherapy, and that quiescent, but not indolent cancer cells, could not escape from immunotherapy.
    "Immunotherapy has become a paradigm shift in medical treatment of disease. Now, instead of our drugs targeting only diseased cells, we can target the immune system and provoke cells of the immune system to do the job for us," said E. John Wherry, Ph.D., Deputy Editor of the Journal of Leukocyte Biology. This new study demonstrates the importance of this concept of exploiting the immune system in cancer to target residual disease that our cancer drugs missed- he said.

  • Republican presidential candidate Carly Fiorina says that “so little” of the charitable donations to the Clinton Foundation “actually go to charitable works” — a figure CARLY for America later put at about 6 percent of its annual revenues — but Fiorina is simply wrong.

    Fiorina and others are referring only to the amount donated by the Clinton Foundation to outside charities, ignoring the fact that most of the Clinton Foundation’s charitable work is performed in-house. One independent philanthropy watchdog did an analysis of Clinton Foundation funding and concluded that about 89 percent of its funding went to charity.

    Simply put, despite its name, the Clinton Foundation is not a private foundation — which typically acts as a pass-through for private donations to other charitable organizations. Rather, it is a public charity. It conducts most of its charitable activities directly.
    ----------------------------------------------------------------------------------------------------
    If you HATE the person, do not beat down on the good work done by the Foundation.

  • Reply to

    DAMN: it is no DOC but FDA is the problem.

    by rvga128 Jul 13, 2016 11:52 AM
    rvga128 rvga128 Jul 13, 2016 1:00 PM Flag

    Do not even go there? Please, that is politics- we did not have hearings for 4000 soldiers killed, 30,000 soldiers injured and 100,000 Iraqis killed yet but we had hearings galore for 4 Americans dead in Libya. In Libya, there was no American Army but in Iraq we had full American force and still lost lives.

  • Reply to

    The Mangement of

    by georgebushke Aug 17, 2016 9:48 AM
    rvga128 rvga128 Aug 17, 2016 9:49 AM Flag

    Right on target.

  • Reply to

    I believe that tomorrow

    by georgebushke Sep 8, 2016 6:25 PM
    rvga128 rvga128 Sep 8, 2016 7:01 PM Flag

    Whatever - you have not yet answered why you post the way you do. Is it because you are a DMB #$%$ DCK
    or it makes you feel better to be a DCK.
    I am not mad at you- I am just asking because you continue not to answer.

  • Reply to

    This is from MINE franchise only!

    by rvga128 Aug 2, 2016 1:07 PM
    rvga128 rvga128 Aug 2, 2016 1:44 PM Flag

    Can not better then this- hey, we waited long enough, but this ride has just started.

  • Reply to

    DAMN: it is no DOC but FDA is the problem.

    by rvga128 Jul 13, 2016 11:52 AM
    rvga128 rvga128 Jul 13, 2016 1:03 PM Flag

    Climbing with Sherpas is a totally different task- damn, this is science. It has to play by the rules. I am not asking too much. I want them yo be fair. I have no beef them letting JUNO go with their study in interest of science - look at my posts earlier I want CAR-T to succeed but I want the same DAMN FDA to look at ADXS the same way. I want them to have the same rules- rules where we can advance science rather then playing DIRTY games- people with diseases need to be cared for- not subjected to fancy GAMES of FDA.

  • Reply to

    Evidence

    by mpreorder Jul 29, 2016 8:48 AM
    rvga128 rvga128 Jul 29, 2016 9:48 AM Flag

    Read op-ed by Zingales from UofChicago: about real capitalism and crony capitalism and how GOP has confused one with the other.

  • rvga128 rvga128 Jul 18, 2016 9:24 AM Flag

    "The glacial slog required to get through the FDA bureaucratic morass"
    Did not slog slowly for JUNO- the corrupt have crept into this agency.

  • Dr. Arta Monjazeb (left), a radiation oncologist with the UC Davis Health System, and Dr. Michael Kent, a veterinary radiation oncologist, collaborated to examine a novel triple therapy to treat metastatic cancer in dogs. Credit: Don Preisler/UC Davis School of Veterinary Medicine

    In my favorite childhood photo, I'm sitting in a big laundry basket in a pile of lab mix puppies. They're licking my face, pulling on my curls and I'm laughing with absolute joy. Dogs are good at teaching us to live in the moment. But did you know they also inform us about diseases we have in common, like cancer?

    Melanoma, lymphoma, gliomas—all of these types of cancer affect both dogs and people. For that reason, dogs make excellent models for better understanding not only how cancer forms in humans, but also in developing more efficient treatments.

    For example, Dr. Michael Kent, a radiation oncologist with the UC Davis School of Veterinary Medicine, collaborated with Dr. Arta Monjazeb, a radiation oncologist at the UC Davis Comprehensive Cancer Center, to examine the use of a novel therapy in treating advanced metastatic disease in dogs. Metastatic tumors are those that have already spread to other parts of the body beyond the main tumor site, which make them the most challenging to treat.

    By combining conventional radiation and immune therapies for the first time in a canine clinical trial, they were able to improve effectiveness of the treatment, and extend the lives of some dogs while maintaining quality of life. Their study results recently appeared in the journal Clinical Cancer Research.

    This was a really nice example of how physicians and veterinarians can work together to tackle a disease that affects both species, said Dr. Kent, who also serves as director of the Center for Companion Animal Health. Now our job is to follow up, refine and improve the technique so it can be used for both dogs and humans, he added.

  • Reply to

    Wrench in CAR-T trials

    by rvga128 Jul 9, 2016 12:17 PM
    rvga128 rvga128 Jul 9, 2016 6:31 PM Flag

    Thanks Ignatius and hdwrsft:
    Always willing to share. But I really see no other play in Cancer Chemotherapy- other than Cell based immunotherapy (bioengineered bacteria or viruses) at present after the debacle in CAR-T for now. In the interest of treating cancer, they (CAR-T) need to rework the kinks and hope they succeed. You need as many different ways to treat different mutation induced cancer as possible. I want CAR-T to succeed too. Smart money needs to move this way for now.

  • rvga128 rvga128 Aug 24, 2016 11:57 AM Flag

    You are not SMART, Trends do not last for long.

  • Reply to

    Taxes in 2017 could be an issue if.....

    by alaniii2001 Aug 9, 2016 9:23 AM
    rvga128 rvga128 Aug 9, 2016 10:10 AM Flag

    I saw that plan of Trumph: More trickle down economics and he is going to take care of middle class people. But some do not vote for their economic interests but then cry when the world passing them by.

  • rvga128 rvga128 Sep 12, 2016 11:29 AM Flag

    I know you can not come with a reasonable explanation. It is free country and you can rain at any time. But you need to be a see a shrink and get help- but you can continue to a DCK and continue mouthing.

  • rvga128 rvga128 Sep 12, 2016 11:09 AM Flag

    georgebushke • Sep 9, 2016 5:36 PM Flag

    0
    users liked this posts
    users disliked this posts
    3
    Reply

    Your right I'm down $57k on ADXS today and I actually bought 3500 shares when we were down $.90 cents. Good news is I made almost half of that back on DWTI. I just would like the pain to stop here. I don't think anyone can be happy with whats happened over the last 30 days and I will argue that we lost all of our momentum when our CEO started discounting shares to unknown individual.
    ----------------------------------------------------------------------------------------------------------------------------------
    That was you .

SGMO
4.57-0.32(-6.54%)Sep 29 4:00 PMEDT